Quality assurance and cancer medicines in low-income and middle-income countries

Chloe Tuck, Kwame Peprah Boaitey, Amy Hai Yan Chan

Research output: Contribution to journalComment/debate/opinionResearchpeer-review

3 Citations (Scopus)

Abstract

[Extract]
Substandard medicines are medicines that fail to meet their quality standards, whereas falsified medicines are those that have been deliberately misrepresented in their identity, composition, or source.1 Both substandard and falsified medicines are a major burden on health and economic outcomes, particularly in low-income and middle-income countries (LMICs).1 WHO reports that one in ten medicines in LMICs might be substandard or falsified,1 although a systematic review suggests higher rates of 11–48%.2 These medicines impact a broad range of therapies, including cancer treatments, antibiotics, and other life-saving therapies.
Original languageEnglish
Pages (from-to)301-303
Number of pages3
JournalThe Lancet Oncology
Volume22
Issue number3
DOIs
Publication statusPublished - Mar 2021

Fingerprint

Dive into the research topics of 'Quality assurance and cancer medicines in low-income and middle-income countries'. Together they form a unique fingerprint.

Cite this